Vyant Bio (VYNT) 10-K 31 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-35817
Entity Registrant Name	VYANT BIO, INC.
Entity Central Index Key	0001349929
Entity Tax Identification Number	04-3462475
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Executive Campus
Entity Address, Address Line Two	2370 State Route 70
Entity Address, Address Line Three	Suite 310
Entity Address, City or Town	Cherry Hill
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08002
City Area Code	(201)
Local Phone Number	479-1357
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VYNT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 24.7
Entity Common Stock, Shares Outstanding		6,267,708
Documents Incorporated by Reference	None.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	34
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Location	Minneapolis, Minnesota

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,041	$ 20,608
Trade accounts and other receivables	323	434
Inventory	53	475
Prepaid expenses and other current assets	747	895
Assets of discontinuing operations – current	345	802
Total current assets	11,509	23,214
Non-current assets:
Fixed assets, net	1,106	1,020
Operating lease right-of-use assets, net	1,542	673
Long-term prepaid expenses and other assets	1,048	1,221
Assets of discontinuing operations – non-current		11,508
Total non-current assets	3,696	14,422
Total Assets	15,205	37,636
Current liabilities:
Accounts payable	655	740
Accrued expenses	1,154	764
Deferred revenue	72	74
Obligations under operating leases, current portion	313	174
Obligation under finance lease, current portion	252	157
Liabilities of discontinuing operations – current	1,219	3,522
Total current liabilities	3,665	5,431
Obligations under operating leases, less current portion	1,301	516
Obligations under finance leases, less current portion	273	293
Long-term debt	57	57
Liabilities of discontinuing operations – non-current		49
Total Liabilities	5,296	6,346
Commitments and Contingencies (Note 16)
Stockholders’ Equity
Preferred stock, authorized 9,764 shares $ 0.0001 par value, 0 shares issued and outstanding as of December 31, 2022 and 2021
Common stock, authorized 100,000 shares, $0.0001 par value, 5,922 and 5,798 shares issued and outstanding as of December 31, 2022 and 2021, respectively	1	1
Additional paid-in capital	111,443	110,176
Accumulated comprehensive loss	(32)	(74)
Accumulated deficit	(101,503)	(78,813)
Total Common Stockholders’ Equity	9,909	31,290
Total Liabilities and Stockholders’ Equity	$ 15,205	$ 37,636

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	9,764	9,764
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	100,000	100,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	5,922	5,798
Common stock, shares outstanding	5,922	5,798

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 666	$ 1,148
Operating costs and expenses:
Research and development	6,772	4,273
Selling, general and administrative	8,798	8,424
Merger related costs		2,310
Total operating costs and expenses	16,578	16,854
Loss from operations	(15,912)	(15,706)
Other income (expense):
Change in fair value of warrant liability		214
Change in fair value of share-settlement obligation derivative		(250)
Loss on debt conversions		(2,518)
Other income	12	57
Interest expense, net	93	(372)
Total other income (expense)	105	(2,869)
Loss from continuing operations before income taxes	(15,807)	(18,575)
Income tax expense (benefit)
Loss from continuing operations	(15,807)	(18,575)
Discontinuing operations (net of ($21) and $0 tax (benefit) expense in 2022 and 2021, respectively)	(6,883)	(22,284)
Net loss	(22,690)	(40,859)
Cumulative translation adjustment	42	(74)
Comprehensive loss	$ (22,648)	$ (40,933)
Net loss per share attributed to common stock – basic and diluted:
Net loss per share from continuing operations	$ (2.69)	$ (4.11)
Net loss per share from discontinuing operations	(1.18)	(4.92)
Net loss per share	$ (3.87)	$ (9.03)
Weighted average shares outstanding:
Weighted average common shares outstanding – basic and diluted	5,868	4,525
Service [Member]
Revenue:
Total revenue	$ 99	$ 665
Operating costs and expenses:
Cost of goods sold – product	44	408
Product [Member]
Revenue:
Total revenue	567	483
Operating costs and expenses:
Cost of goods sold – product	$ 964	$ 1,439

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Income tax benefit	$ 21	$ 0

Consolidated Statements of Temp

Consolidated Statements of Temporary Equity and Common Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series A Preferred Stock [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Temporary equity [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 12,356	$ 16,651		$ 29,007		$ 1,514	$ (37,954)		$ (36,440)
Beginning balance, shares at Dec. 31, 2020	4,612,000	3,489,000			519,000
Stock-based compensation						1,298			1,298
Exercise of stock options						41			$ 41
Exercise of stock options, shares					1,000				7,419
Foreign currency translation adjustment								(74)	$ (74)
Net loss							(40,859)		(40,859)
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214			$ 1,786	1,786
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214, shares			567,000
Issuance of Common Stock for acquisition consideration						59,920			59,920
Issuance of Common Stock for acquisition consideration, shares					2,201,000
Issuance of Incremental shares to StemoniX shareholders upon Merger
Issuance of incremental shares to StemoniX shareholders upon Merger, shares					161,000
Conversion of Preferred Stock to Common Stock upon Merger	$ (12,356)	$ (16,651)	$ (1,786)	(30,793)	$ 1	30,792			30,793
Conversion of Preferred Stock to Common Stock upon Merger, shares	(4,612,000)	(3,489,000)	(567,000)		2,239,000
Conversion of 2020 Notes to Common Stock upon Merger						16,190			16,190
Conversion of 2020 Notes to Common Stock upon Merger, shares					668,000
Preferred stock warrant settled for Common Stock upon Merger
Preferred stock warrant settled for Common Stock upon Merger, shares					9,000
Warrant liability reclassified to equity upon Merger						421			421
Ending balance, value at Dec. 31, 2021					$ 1	110,176	(78,813)	(74)	31,290
Ending balance, shares at Dec. 31, 2021					5,798,000
Stock-based compensation						1,455			1,455
Exercise of stock options						4			$ 4
Exercise of stock options, shares					1,000				1,034
Vesting of restricted stock
Vesting of restricted stock, shares					2,000
Issuance of common stock, net of issuance costs of $250						(192)			(192)
Issuance of common stock, net of issuance costs, shares					121,000
Foreign currency translation adjustment								42	42
Net loss							(22,690)		(22,690)
Ending balance, value at Dec. 31, 2022					$ 1	$ 111,443	$ (101,503)	$ (32)	$ 9,909
Ending balance, shares at Dec. 31, 2022					5,922,000

Consolidated Statements of Te_2

Consolidated Statements of Temporary Equity and Common Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Series C Preferred Stock [Member]
Payments of Stock Issuance Costs	$ 214

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (22,690)	$ (40,859)
Net loss from discontinuing operations	6,883	22,284
Reconciliation of net loss to net cash used in operating activities, continuing operations:
Stock-based compensation	1,186	1,003
Amortization of operating lease right-of-use assets	321	504
Depreciation and amortization expense	522	550
Change in fair value of share-settlement obligation derivative		250
Change in fair value of financial instruments		(210)
Accretion of debt discount		173
Loss on conversion of debt		2,518
Other	(1)	(14)
Changes in operating assets and liabilities, net of impacts of business combination:
Trade accounts and other receivables	111	(77)
Inventory	422	(60)
Prepaid expense and other assets	321	(165)
Accounts payable	(85)	(1,146)
Obligations under operating leases	(265)	(499)
Accrued expenses and other liabilities	387	(740)
Net cash used in operating activities, continuing operations	(12,888)	(16,488)
Net cash used in operating activities, discontinuing operations	(793)	(505)
Net cash used in operating activities	(13,681)	(16,993)
Cash Flows from Investing Activities:
Purchase of equipment	(617)	(535)
Proceeds from patent held for sale and equipment sales		50
Cash acquired from acquisition		30,163
Net cash (used in) provided by investing activities, continuing operations	(617)	29,678
Net cash provided by (used in) investing activities, discontinuing operations	3,880	(59)
Net cash provided by investing activities	3,263	29,619
Cash Flows from Financing Activities:
Issuance of common stock, net of issuance costs	(188)	41
Issuance of Series C Convertible Preferred Stock, net of issuance costs		1,786
2020 Convertible Note proceeds, net of issuance costs		5,022
Principal payments on long-term debt		(82)
Proceeds from lease financing	266	492
Principal payments on obligations under financing leases	(191)	(37)
Net cash (used in) provided by financing activities, continuing operations	(113)	7,222
Net cash used in financing activities, discontinuing operations	(36)	(32)
Net cash (used in) provided by financing activities	(149)	7,190
Net (decrease) increase in cash and cash equivalents	(10,567)	19,816
Cash and cash equivalents, beginning of year	20,608	792
Cash and cash equivalents, end of year	10,041	20,608
Supplemental disclosure of cash flow information:
Cash paid for interest	34	8
Cash paid for income taxes	8
Non-cash investing activities:
Fair value of non-cash merger consideration		59,920
Right-of-use assets obtained in exchange for new operating lease liabilities	1,189	83
Non-cash financing activities:
Conversion of Convertible Preferred Stock to Common Stock upon Merger		30,793
Conversion of 2020 Convertible Notes and accrued interest to Common Stock upon Merger		16,190
Reclass warrant liability to equity upon Merger		$ 421

Organization, Description of Bu

Organization, Description of Business, Business Disposals, Offerings and Merger	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Description of Business, Business Disposals, Offerings and Merger	Note 1. Organization, Description of Business, Business Disposals, Offerings and Merger Vyant Bio, Inc. (the “Company”, “Vyant Bio”, “VYNT” or “we”) , As further described in Note 3, i n December 2021, the Company’s Board of Directors approved a plan to sell the vivo vivo vivo The Company is expected to generate minimal revenue from continuing operations as we have substantially ceased the Maple Grove facility’s revenue producing operations to support internal drug discovery programs. The Company had cash and cash equivalents of $ 10.0 101.5 12.8 15.8 20,000,000 15,000,000 Going Concern The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has suffered recurring losses and negative cash flows from operations since inception, has an accumulated deficit, and is expected to generate minimal revenue from continuing operations as we have substantially ceased the Maple Grove facility’s revenue producing operations to support internal drug discovery programs. The Company is projecting insufficient liquidity to meet its obligations as they become due over the next twelve months. The Company had cash and cash equivalents of $ 10.0 101.5 12.8 15.8 20,000,000 15,000,000 In response to these conditions and based on our current operating plan, the Company plans to reduce expenses, slow cash flows, and evaluate strategic partners to acquire our assets, including our public company as a reverse merger candidate. There are no assurances that we will be able to raise cash in these transactions or find a reverse merger candidate and we may therefore need to complete an orderly winddown of the Company’s operations or, if sufficient funds are not available, bankruptcy. These plans have not yet been finalized and are not within the Company’s control, and therefore cannot be deemed probable. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Dollar amounts in tables are stated in thousands of U.S. dollars.

Cancer Genetics, Inc. Merger

Cancer Genetics, Inc. Merger	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Cancer Genetics, Inc. Merger	Note 2. Cancer Genetics, Inc. Merger The Company formerly known as Cancer Genetics, Inc. (“CGI”), StemoniX and CGI Acquisition, Inc. (“Merger Sub”) entered into a merger agreement on August 21, 2020, which was amended on February 8, 2021 and February 26, 2021 (as amended, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub was merged (the “Merger”) with and into StemoniX on March 30, 2021, with StemoniX surviving the Merger as a wholly owned subsidiary of the Company. For U.S. federal income tax purposes, the Merger qualified as a tax-free “reorganization”. Concurrent with the Merger closing, the Company changed its name to Vyant Bio, Inc. Under the terms of the Merger Agreement, upon consummation of the Merger, the Company issued (i) an aggregate of 3,595,508 shares of VYNT common stock, par value $ 0.0001 per share (the “Common Stock”) to the holders of StemoniX capital stock (after giving effect to the conversion of all StemoniX preferred shares and StemoniX 2020 Convertible Notes) and StemoniX warrants (which does not include a certain warrant (the “Major Investor Warrant”) issued to a certain StemoniX convertible note holder (the “Major Investor”)), (ii) options to purchase an aggregate of 178,356 shares of Common Stock to the holders of StemoniX options with exercise prices ranging from $ 3.30 to $ 23.05 per share and a weighted average exercise price of $ 7.30 per share, and (iii) a warrant (the “Major Investor Warrant”) to the Major Investor, expiring February 23, 2026 to purchase 28,778 shares of Common Stock at a price of $ 29.5295 per share in exchange for the Major Investor Warrant. The Merger was accounted for as a reverse acquisition with StemoniX being the accounting acquirer of CGI using the acquisition method of accounting. Under acquisition accounting, the assets and liabilities (including executory contracts, commitments and other obligations) of CGI, as of March 30, 2021, the closing date of the Merger, were recorded at their respective fair values and added to those of StemoniX. Any excess of purchase price consideration over the fair values of the identifiable net assets is recorded as goodwill. The total consideration paid by StemoniX in the Merger amounted to $ 59.9 2,201,437 50.74 431,537 9.04 11,181 139 160,942 The Company incurred $ 2.3 The following details the allocation of the preliminary purchase price consideration recorded on March 30, 2021, the acquisition date, with adjustments recorded through the first quarter of 2022, the end of the purchase price allocation period. Schedule of Preliminary Allocation of Purchase Price Consideration Preliminary Adjustments Final Assets acquired: Cash and equivalents $ 30,163 $ - $ 30,163 Accounts receivable 705 - 705 Other current assets 806 227 1,033 Intangible assets 9,500 - 9,500 Fixed assets 416 (256 ) 160 Goodwill 22,164 216 22,380 Long-term prepaid expenses and other assets 1,381 - 1,381 Total assets acquired $ 65,135 $ 187 $ 65,322 Liabilities assumed: Accounts payable and accrued expenses $ 2,670 $ 437 $ 3,107 Current liabilities of discontinuing operations 588 (141 ) 447 Obligations under operating leases 198 - 198 Obligations under finance leases 106 - 106 Deferred revenue 1,293 (114 ) 1,179 Payroll and income taxes payable 360 5 365 Total liabilities assumed $ 5,215 $ 187 $ 5,402 Net assets acquired $ 59,920 $ - $ 59,920 The Company substantially completed valuation analyses necessary to assess the fair values of the tangible and intangible assets acquired and liabilities assumed and the amount of goodwill to be recognized as of the acquisition date. Fair values were based on management’s estimates and assumptions. The Company recognized intangible assets related to the Merger, which consist of the tradename valued at $ 1.5 million with an estimated useful life of ten years and customer relationships valued at $ 8.0 million with an estimated useful life of ten years vivo 1.0 % royalty rate was appropriate given the business-to-business nature of the vivo vivo Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivo . These intangible assets are classified as Level 3 measurements within the fair value hierarchy. The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2021: Schedule of Proforma Financial Information Year ended December 31, 2021 Total revenue $ 6,726 Net loss (35,623 ) Pro forma loss per common share, (6.15 ) Pro forma weighted average number of common shares basic and diluted 5,795,498 The pro forma combined results of operations are not necessarily indicative of the results of operations that actually would have occurred had the Merger been completed as of January 1, 2021, nor are they necessarily indicative of future consolidated results.

Discontinuing Operations

Discontinuing Operations	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinuing Operations	Note 3. Discontinuing Operations I n December 2021, the Company’s Board of Directors approved a plan to sell the vivo vivo vivo On November 2, 2022 the Company completed the sale of its principal vivo vivo 5.5 million in an upfront cash payment, subject to customary adjustments for working capital, closing cash, indebtedness and transaction expenses. After these closing adjustments were reflected, $ 5.5 million was paid at closing and an additional $ 0.3 4.8 million in cash after transaction related expenses and income taxes, as well as incur $ 0.4 million in exit costs associated with this transaction. Exit costs associated with the vivo vivo 357 thousand. On December 30, 2022, the Company entered into a Share Purchase Agreement (the “Agreement”) with Sabine Brandt as trustee for the Brandt Family Trust (“Buyer”), pursuant to which vivo vivo vivo vivo 827 thousand and the assumption by Buyer of liabilities of the sold entities aggregating to approximately $ 2.0 million. The Transaction was consummated effective December 31, 2022. The Agreement contains customary representations, warranties, covenants and indemnification provisions. As further described in note 17, the Company sold the remainder of the vivo In connection with the classification of the vivo 20.2 5.4 2.2 2.7 0.5 Also included in discontinuing operations are pre-Merger-related payables related to Cancer Genetics’ sale of its BioPharma and Clinical businesses (“Pre-Merger discontinuing operations”). As of December 31, 2022 and 2021, $ 267 409 Results of discontinuing operations were as follows: Schedule of Disposal Groups Including Discontinuing Operations from Income Statement 2022 2021 Years ended December 31, 2022 2021 Revenue $ 6,406 $ 3,978 Cost of goods sold 3,189 2,524 General and administrative 4,709 3,531 Impairment of goodwill and intangible assets 5,415 20,216 Total operating costs and expenses $ 13,313 $ 26,271 Loss from discontinuing operations $ (6,907 ) $ (22,293 ) Total other income $ 3 $ 9 Loss from discontinuing operations before income taxes $ (6,904 ) $ (22,284 ) Income tax expense (benefit) (21 ) - Net loss from discontinuing operations $ (6,883 ) $ (22,284 ) Asset and liabilities of discontinuing operations were as follows: Schedule of Disposal Groups Including Discontinuing Operations from Balance Sheet 2022 2021 December 31, 2022 2021 Accounts receivable $ 11 $ 457 Due from Reaction Biology Corporation 334 Other current assets - 345 Assets of discontinuing operations - current $ 345 $ 802 Fixed assets, net of accumulated depreciation $ - $ 163 Operating lease right-of-use assets - 30 Patents and other intangible assets, net - 8,787 Goodwill - 2,164 Other assets - 364 Assets of discontinuing operations - non-current $ - $ 11,508 Accounts payable $ 47 $ 358 Due to RDDT a vivoPharm Company Pty Ltd 216 Accrued expense 577 418 Obligation under operating lease, current - 29 Obligation under finance lease, current - 32 Deferred revenue 43 1,911 Taxes payable 69 365 Other current liabilities 267 409 Liabilities of discontinued operations - current $ 1,219 $ 3,522 Obligations under operating leases, less current $ - $ 2 Obligations under finance leases, less current - 47 Liabilities of discontinued operations -non- current $ - $ 49 There were no Schedule of Intangible Assets 2021 Intangible Assets: Customer relationships $ 8,000 Trade name 1,500 Intangible assets gross 9,500 Less accumulated amortization (713 ) Intangible assets, net $ 8,787 Amortization expense for intangible assets aggregated $ 713 no Goodwill arising from the Merger was solely attributed to the vivo Schedule of Goodwill Rollforward Beginning balance, January 1, 2021 $ - Initial balance upon consummation of the Merger 22,164 Purchase price adjustments 216 Impairment charge (20,216 ) Ending balance, December 31, 2021 $ 2,164 Impairment charge (2,164 ) Ending balance, December 31, 2022 $ -

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Note 4. Significant Accounting Policies Basis of presentation Segment reporting vivo vivo vivo vivo vivo Principles of consolidation Foreign currency : The Company translates the financial statements of its foreign subsidiaries, which have a functional currency in the respective country’s local currency, to U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue, costs and expenses. Translation gains and losses are recorded in accumulated comprehensive loss as a component of stockholders’ equity. For the years ended December 31, 2022 and 2021 there were foreign currency translation gains of $ 42 74 thousand, respectively, all related to the vivo Use of estimates vivo Risks and uncertainties Cash and cash equivalents 8.6 12.0 Revenue recognition The Company’s primary sources of revenue are product sales from the sale of microOrgan® plates and the performance of preclinical drug testing services using the microOrgan technology. The Company does not act as an agent in any of its revenue arrangements. For product contracts, revenue is recognized at a point-in-time upon delivery to the customer, which is generally deemed to occur upon shipment. Product contracts with customers generally state the terms of the sale, including the quantity and price of each product purchased. Payment terms and conditions may vary by contract, although terms generally include a requirement of payment within a range of 30 to 90 days after the performance obligation has been satisfied. As a result, the contracts do not include a significant financing component. In addition, contacts typically do not contain variable consideration as the contracts include stated prices. The Company provides assurance-type warranties on all of its products, which are not separate performance obligations. For service contracts, revenue is recognized over time and is generally defined pursuant to an enforceable right to payment for performance completed on service projects for which the Company has no alternative use as customer furnished compounds are added to Company plates for testing. The Company does not obtain control of the customer furnished compounds as the Company does not have the ability to direct their use. Revenue is measured by the costs incurred to date relative to the estimated total direct costs to fulfill each contract (cost-to-cost method). Incurred costs represent work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, materials and overhead. Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced or paid by the Company’s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Company’s revenue recognition criteria described above. The Company records all amounts collected for shipping as revenue. Amounts collected from customers for sales tax are recorded in sales net of amounts paid to related taxing authorities. The Company may include subcontractor or third-party vendors in certain integrated services arrangements. In these arrangements, revenue from sales of third-party vendor services is generally recorded gross as revenue and cost of goods sold - service, as the Company is the principal for the transaction. When the Company is acting as an agent between a customer and the vendor services, the Company does not record revenue and vendor costs are recorded net within cost of goods sold - service. To determine whether the Company is an agent or principal, the Company considers whether it obtains control of services before they are transferred to the customer. In making this evaluation, several factors are considered, most notably whether the Company has primary responsibility for fulfillment to the client, as well as fiscal risk and pricing discretion. There were no contract assets from continuing operations as of December 31, 2022. There were contract assets from continuing operations of $ 70 thousand as of December 31, 2021. Contract liabilities from continuing operations related to unfulfilled performance obligations were $ 72 74 75 43 1.9 Trade accounts receivable No Other receivables 252 100 252 205 Concentration of credit risk : Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade receivables. The Company places cash and cash equivalents in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. As of December 31, 2022 and 2021, one and four customers, respectively, represented 10% or more of the Company’s total trade accounts receivable, and in the aggregate, these customers represented 100 %, or $ 71 78 %, or $ 262 thousand, respectively, of the Company’s total trade accounts receivable. Inventory Prepaid expenses and other assets 2.7 , 797 1.0 Deferred revenue Fixed assets The estimated useful life of equipment is five years Long-lived assets, such as fixed assets subject to depreciation, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If circumstances require a long-lived asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset group to its carrying amount. If the carrying amount of the long-lived asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. As of December 31, 2022 and 2021 the Company determined that there were no indicators of impairment and did not recognize any fixed asset impairment use in continuing operations. Goodwill 22.4 vivo vivo 20.2 2.2 Convertible notes Fair value option Warrants The Company issued a warrant during first quarter of 2021 that contained an indexation feature not indexed to the Company’s stock resulting in this warrant being accounted for as a derivative. Derivative warrants are recorded as liabilities in the accompanying consolidated balance sheets. These common stock purchase warrants do not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using the Black-Scholes valuation pricing model with the assumptions as follows: the risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. The Company uses the historical volatility of its common stock and the closing price of its shares on the NASDAQ Capital Market. As further described in Note 10 to the consolidated financial statements, as a result of the Merger, the terms of this warrant were finalized through the conversion to a Vyant Bio warrant resulting in the Vyant Bio warrant being equity classified. Derivative instruments Income taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits and penalties in income tax expense. The Company elects to present deferred taxes and the effect of unrecognized tax benefits associated with the held for sale assets and liabilities as part of the assets (or liabilities) held for sale. The deferred taxes primarily relate to net operating loss carryforwards in US and foreign jurisdictions that are classified as held for sale. Due to a valuation allowance recorded against the deferred tax assets, the net impact of deferred tax assets included in the held for sale assets and liabilities is $ 0 Leases For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company has elected the practical expedient to account for lease and non-lease components as a single lease component. Therefore, the lease payments used to measure the lease liability includes all of the fixed consideration in the contract. Key estimates and judgments include how the Company determines (1) the discount rate it uses to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. The Company discounts its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Generally, the Company cannot determine the interest rate implicit in the lease because it does not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company generally uses its incremental borrowing rate as the discount rate for the lease. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company does not generally borrow on a collateralized basis, it uses the interest rate it pays on its non-collateralized borrowings as an input to deriving an appropriate incremental borrowing rate, adjusted for the lease payments, the lease term and the effect on that rate of designating specific collateral with a value equal to the unpaid lease payments for that lease. The lease term for all the Company’s leases includes the noncancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Intangible assets vivo ten years vivo no 713 Research and development 6.8 4.3 Advertising costs were $ 28 34 Stock-based compensation Commitments and contingencies Fair value measurements ● Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. ● Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Valuation of business combination Subsequent events Net loss per share

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Note 5. Inventory The Company’s inventory consists of the following: Schedule of Inventory December 31, 2022 December 31, 2021 Finished goods $ - $ 23 Work in process 9 138 Raw materials 44 314 Total inventory $ 53 $ 475

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6. Fixed Assets Presented in the table below are the major classes of fixed assets by category: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Equipment $ 2,962 $ 2,733 Furniture and fixtures 6 6 Leasehold improvements 612 251 Fixed assets, gross 3,580 2,990 Less accumulated depreciation (2,474 ) (1,970 ) Fixed assets, net $ 1,106 $ 1,020 Depreciation expense from continuing operations for the years ended December 31, 2022 and 2021 was $ 522 550

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	Note 7. Leases During October 2021, the Company entered into a new $ 491 As of December 31, 2022, the Company leased facilities in Maple Grove, Minnesota and in San Diego, California under arrangements which expire in 83 1.2 The components of operating and finance lease expense in continuing operations for the years ended December 31, are as follows: Schedule of Components of Lease Expense and Supplemental Information 2022 2021 Operating lease cost $ 441 $ 504 Finance lease cost: Depreciation of ROU assets $ 204 $ 35 Interest on lease liabilities 34 8 Total finance lease cost: $ 238 $ 43 Variable lease costs $ - $ - Short-term lease costs - - Total lease continuing operations expense $ 679 $ 547 Amounts reported in the consolidated balance sheet from continuing operations as of December 31, 2022 and 2021 are as follows: Schedule of Amounts Reported in the Consolidated Balance Sheet 2022 2021 Operating leases: Operating lease ROU assets, net $ 1,542 $ 673 Operating lease current liabilities $ 313 $ 174 Operating lease long-term liabilities 1,301 516 Total operating lease liabilities $ 1,614 $ 690 Finance leases: Equipment $ 744 $ 477 Accumulated depreciation (244 ) (63 ) Finance leases, net $ 500 $ 414 Current installment obligations under finance leases $ 252 $ 157 Long-term portion of obligations under finance leases 273 293 Total finance lease liabilities $ 525 $ 450 Equipment subject to finance leases are classified within fixed assets, net, on the accompanying consolidated balance sheets. Supplemental cash flow related to operating and finance leases of the Company’s continuing operations is as follows for the years ended December 31, 2022 and 2021: 2022 2021 Cash paid amounts included in the measurement of lease liabilities from continuing operations: Operating cash flows used for operating leases $ (265 ) $ (509 ) Financing cash flows used for finance leases $ (191 ) $ (37 ) Financing cash flows provided by finance leases $ 266 $ 492 Other supplemental information related to operating and finance leases of the Company’s continuing operations is as follows as of December 31, 2022 and 2021: 2022 2021 Weighted average remaining lease term (in years): Operating leases 4.45 5.42 Finance leases 2.05 2.75 Weighted average discount rate: Operating leases 8.30 % 9.88 % Finance leases 6.90 % 6.54 % Annual future payments of lease liabilities under noncancelable leases as of December 31, 2022 are as follows: Schedule of Annual Payments of Lease liabilities Under Noncancelable leases Operating leases Finance leases 2023 $ 433 $ 280 2024 423 235 2025 427 50 2026 441 - 2027 215 - Thereafter - - Total undiscounted lease payments 1,939 566 Less: imputed interest (325 ) (41 ) Total lease liabilities $ 1,614 $ 525

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. Income Taxes The components of loss before income taxes from continuing operations consist of the following. Schedule of Components of Loss Before Income Tax From Continuing operations 2022 2021 United States $ (15,807 ) $ (18,575 ) Foreign - - Total loss before income taxes $ (15,807 ) $ (18,575 ) The Company did not record any current, deferred, or net income tax expense (benefit) from continuing operations in 2022 or 2021. Total income tax expense (benefit) from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% Schedule of Components of Income Tax Expense Benefit 2022 2021 Computed “expected” tax expense $ (3,219 ) $ (3,901) Deferred rate change (132 ) 84 State taxes, net of federal tax effect (822 ) (752) Non-deductible transaction costs - 222 Non-deductible interest 2 664 R&D tax credit 238 (238) Sale of vivo Pharm business (72 ) Other, net 117 (51) Change in valuation allowance 3,888 3,972 Income tax expense (benefit) $ - $ - The tax effects of temporary differences from continuing operations that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below as of December 31: Components of Approximate Deferred tax 2022 2021 Deferred tax assets Accrued liabilities $ 109 $ 47 Capitalized R&D costs 3,233 1,931 Intangibles 107 127 Fixed assets 2 - Stock compensation 248 160 Lease liability 478 170 Loss carryforward 20,750 18,144 Tax credit carryforward 1,085 1,406 Other temporary differences 3 4 Total gross deferred tax assets 26,015 21,989 Valuation allowance (25,614 ) (21,807 ) Total deferred tax assets $ 401 $ 182 Deferred tax liabilities Fixed assets $ - $ (17 ) Lease assets (401 ) (165 ) Total gross deferred tax liabilities $ (401 ) $ (182 ) Net deferred tax asset $ - $ - The Company assessed that the valuation allowance against its deferred tax assets is still appropriate as of December 31, 2022 and 2021, based on the consideration of all available positive and negative evidence using the “more likely than not” standard required when accounting for income taxes. Under the Code, certain corporate stock transactions into which the Company has entered or may enter in the future could limit the amount of the net operating loss carryforwards that can be utilized in future periods. The Company has completed a review of historical stock transactions, as well as the current stock transactions completed in conjunction with the Merger and concluded our federal net operating loss and R&D credit carryforwards are subject to limitations under Section 382 and 383 of the Internal Revenue Code. As of December 31, 2022, the Company has federal net operating loss carryforwards of $ 78.3 11.9 66.4 On August 9, 2022, the Creating Helpful Incentives to Produce Semiconductors (“CHIPS”) Act was signed into law creating a new advanced manufacturing investment credit under new Internal Revenue Code section 48D. On August 16, 2022, the Inflation Reduction Act (IRA) was signed into law, which, among other changes, created a new corporate alternative minimum tax (AMT) based on adjusted financial statement income and imposes a 1 As of December 31, 2022 and 2021, the Company had no liability for unrecognized tax benefits recorded in continued operations. The Company does not expect the liability for unrecognized tax benefits to change in the next twelve months. The Company has elected to classify tax-related accrued interest and penalties as a component of income tax expense. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. As of December 31, 2022, the Company was no longer subject to income tax examinations for taxable years before 2019 in the case of U.S. federal taxing authorities, and taxable years generally before 2018 in the case of state and local taxing jurisdictions.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Note 9. Long-Term Debt Long-term debt consists of the following: Schedule of Long- term Debt December 31, December 31, Economic Injury Disaster Loan $ 57 $ 57 Total long-term debt $ 57 $ 57 Future annual principal repayments due on the long-term debt as of December 31, 2022 are as follows: Schedule of Future Annual Principal Repayments Due on Long - term Debt Amount 2023 $ 1 2024 1 2025 1 2026 1 2027 1 Thereafter 52 Total $ 57 Department of Employment and Economic Development (“DEED”) loan On March 10, 2015, the Company received an interest free loan with a loan maturity date of March 10, 2022 from the Minnesota DEED under the State Small Business Credit Initiative Act of 2010. The funds were received under the Angel Loan Fund Program which are provided to early-stage small businesses for financial support through direct loans. Upon consummation of the merger with CGI on March 30, 2021, the Company triggered the 30% repayment premium and this loan was repaid. 2020 Convertible Notes Effective February 8, 2021 the Company’s shareholders and 2020 Convertible Note holders approved amendments to the 2020 Convertible Notes to allow for the issuance of up to $ 10.0 3.9 3.0 10.0 5.0 3.9 For any Major Investor, the modified terms provide for a fixed conversion discount on the 2020 Convertible Notes of 20% and a common stock warrant equal to 20% of the amount invested in all 2020 Convertible Notes by such Major Investor divided by the weighted average share price of the Common Stock over the five trading days prior to the closing of the Merger 1.25 3.0 28,778 29.5295 12.7 468 667,788 2.5 18.22% Paycheck Protection Program Loan In April 2020, the Company applied for and received a $ 730 730 Economic Injury Disaster Loan In 2020 the Company received a $ 57 thousand Economic Injury Disaster Loan (“EIDL”) loan from the Small Business Administration in connection with the COVID-19 impact on the Company’s business. This loan bears interest at 3.75 % and is repayable in monthly installments starting in June 2022 with a final balance due on June 21, 2050.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 10. Stockholders’ Equity Common Stock Holders of common stock are entitled to one vote per share, to receive dividends if and when declared, and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up and dissolution of the Company. Reverse Stock Split On July 14, 2022, the Company’s stockholders approved a reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of Common Stock in the range of one for five to one for fifteen shares. On October 18, 2022, the Company’s Board of Directors approved a Reverse Split of one for five shares effective November 1, 2022. As a result of the reverse split, every 5 shares of the Company’s Common Stock issued and outstanding were converted into one share of Common Stock. No fractional shares were issued in connection with the reverse split. Stockholders who would otherwise be entitled to a fractional share of Common Stock instead received cash in lieu of fractional shares based on the average of the closing sales prices of the Company’s Common Stock as quoted on the Nasdaq Capital Market on the five trading days immediately prior to November 1, 2022. The reverse split did not reduce the number of authorized shares of the Common Stock or preferred stock (the “Preferred Stock”) or change the par values of the Company’s Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder’s ownership percentage of the Company’s shares of Common Stock (except to the extent that the reverse split would result in some of the stockholders receiving cash in lieu of fractional shares). All outstanding common stock options, warrants and restricted stock units entitling their holders to receive or purchase shares of the Company’s Common Stock have been adjusted as a result of the reverse split, as required by the terms of each security. All historical share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the Reverse Split. Lincoln Park Capital Fund, LLC Agreement On March 28, 2022, the Company entered into a purchase agreement, or Purchase Agreement, with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which, subject to the terms and conditions, provides that the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $ 15.0 81,190 At The Market Financing On April 8, 2022, the Company entered into an Equity Distribution Agreement with Canaccord Genuity LLC (the “Canaccord”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 20,000,000 41,162 As further described in Note 17, on March 23, 2023, the Company terminated the arrangements with both Lincoln Park and Canaccord. For the year ended December 31, 2022, the Company incurred $ 250 thousand of issuance costs related to Lincoln Park and Canaccord Genuity LLC ATM arrangements which were recorded in the Condensed Consolidated Statements of Stockholders’ Equity. Preferred Stock Series A and B Preferred Stock As of December 31, 2020, the Company had 4,611,587 3,489,470 5,973,509 4,524,171 he related carrying value was reclassified to common stock and additional paid-in capital. Series C Preferred Stock Effective March 15, 2021, StemoniX shareholders approved the Merger with Cancer Genetics and the authorization of $ 2.0 699,395 he related carrying value was reclassified to common stock and additional paid-in capital. Effective with the Merger, all Series A, B and C Preferred shares were converted to StemoniX common stock which were exchanged for Vyant Bio common stock. As of December 31, 2022, the Company is authorized to issue 9.8 Warrants Common Stock Warrant The Company issued the Major Investor Warrant on February 23, 2021. Effective with the Merger, the Major Investor Warrant was exchanged for a warrant to purchase 28,778 29.5295 214 421 In connection with the Merger, the Company assumed 431,537 426,361 Summary of Common Stock Warrants Outstanding Issuance Related to: Exercise Price Outstanding Warrants Expiration Dates 2020 Convertible Note $ 29.55 28,778 Feb 23, 2026 2021 offerings $ 17.50 324,828 Feb 10, 2026 - Aug 3, 2026 Advisory fees $ 12.10 37.95 98,578 Jan 9, 2024 - Oct 28, 2025 Debt $ 138.00 2,955 Mar 22, 2024 Total 455,139 Preferred Stock Warrants In connection with the issuance of the Series A Convertible Preferred and Series B Convertible Preferred, the Company issued warrants (the “Series A Warrants” and “Series B Warrants”, respectively, and collectively, the “Preferred Warrants”) as compensation to non-employee placement agents. The Series A Warrants and Series B Warrants were issued on April 28, 2017 and May 18, 2019, respectively. The Company determined the Preferred Warrants should be classified as equity as they were issued as vested share-based payment compensation to nonemployees. The Preferred Warrants were recorded in stockholders’ equity at fair value upon issuance with no subsequent remeasurement. As part of the Merger, the Preferred Warrants were converted and settled for a total of 8,621

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 11. Fair Value Measurements During the first quarter of 2021, the Company elected to account for the $ 3.0 The fair value of the Company’s 2020 Convertible Note issued to the Major Investor is measured as the sum of the instrument’s parts, being the underlying debt instrument and the conversion feature. The conversion feature was valued using the probability weighted conversion price discount. The instrument provided the holder the right to convert the instrument into shares of Series B Preferred Stock at a 20% discount. Given the timing of the issuance of the instrument near the Merger date, management determined that there was a 99.5% probability of the holders converting the instrument to Company shares at a 20% discount The Company valued the warrants issued with the 2020 Convertible Notes using a Black-Scholes-Merton model using the value of the underlying stock and exercise price of $ 2.01 0.59 86 5 years The Company’s 2020 Convertible Notes contain a share settled redemption feature (“Embedded Derivative”) that requires conversion at the lesser of specified discounts from qualified financing price per share or the fair value of the common stock at the time of conversion. The discount changes based on the passage of time between issuance of the convertible note and the conversion event. This feature is considered a derivative that requires bifurcation because it provides a specified premium to the holder of the note upon conversion. The Company measures the share-settlement obligation derivative at fair value based on significant inputs that are not observable in the market. This results in the liability classified as a Level 3 measurement within the fair value hierarchy. Upon the Merger, all of the Level 3 instruments were exchanged for Vyant Bio equity classified instruments. Prior to their exchange, all of these instruments were marked to their fair market values with corresponding changes recorded in the statement of operations in the first quarter of 2021. In the fourth quarter of 2021, the Company classified the vivo vivo vivo 4.5 million decrease to the fair value of vivo 4.3 million during the quarter ended March 31, 2022, which decreased vivo 9.2 million as of December 31, 2021 to $ 4.9 million. During the second quarter of 2022, the Company received two offers for mutually exclusive components of the vivo 1.5 million during the second quarter of 2022. The Company recorded an impairment recovery of $ 388 thousand during the third quarter of 2022 based upon September 30, 2022 vivo vivo 106 The following tables present changes in fair value of level 3 valued instruments as of and for the years ended December 31, 2022 and 2021: Schedule of Changes in Fair Value of Level 3 Valued Instruments vivo Balance - January 1, 2022 $ 11,000 Additions - Measurement adjustments (5,528 ) Sale of vivo (5,472 ) Balance - December 31, 2022 $ - The following tables present changes in fair value of level 3 valued instruments for the year ended December 31, 2021: 2020 Convertible Note Warrant Embedded Derivative vivo Balance - January 1, 2021 $ - $ - $ 1,690 $ - Additions 3,746 635 325 11,000 Measurement adjustments 4 (214 ) 250 - Settlement (3,750 ) (421 ) (2,265 ) - Balance - December 31, 2021 $ - $ - $ - $ 11,000

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Loss Per Share	Note 12. Loss Per Share Basic loss per share is computed by dividing the net loss after tax attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is computed by including potentially dilutive securities outstanding during the period in the calculation of weighted average shares outstanding. The Company did not have any dilutive securities during the periods presented; therefore, diluted loss per share is equal to basic loss per share. Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted loss per share calculations for the years ended December 31, 2022 and 2021: Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share 2022 2021 December 31, 2022 2021 Net loss from continuing operations $ (15,807 ) $ (18,575 ) Net loss from discontinuing operations (6,883 ) (22,284 ) Net loss $ (22,690 ) $ (40,859 ) Basic and diluted weighted average shares outstanding 5,868,402 4,522,889 Basic and diluted net loss per share: Continuing operations $ (2.69 ) $ (4.11 ) Discontinuing operations (1.18 ) (4.92 ) Net loss $ (3.87 ) $ (9.03 ) The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2022 and 2021 because the effect would be anti-dilutive: Schedule of Computation of Diluted Shares Outstanding December 31, 2022 2021 Common Stock warrants 455,139 459,382 Common Stock options 428,301 464,019 Restricted stock 77,104 - Total 960,544 923,401 Anti-dilutive securities 960,544 923,401

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 13. Stock-Based Compensation The Company has three legacy equity incentive plans: the Cancer Genetics, Inc. 2008 Stock Option Plan (the “2008 Plan”) and the Cancer Genetics Inc. 2011 Equity Incentive Plan (the “2011 Plan”), and the StemoniX Inc. 2015 Stock Option Plan (the “2015 Plan”, and together with the 2008 Plan, and the 2011 Plan, the “Frozen Stock Option Plans”). The Frozen Stock Option Plans as well as the 2021 Plan (as defined below) are meant to provide additional incentive to officers, employees and consultants to remain in the Company’s employment. Options granted are generally exercisable for up to 10 38,376 Effective with the Merger, the Vyant Bio 2021 Equity Incentive Plan (the “2021 Plan”) came into effect, pursuant to which the Company’s Board of Directors may grant up to 900,000 230,300 15,618 1,735 25% As StemoniX was the acquirer for accounting purposes, the pre-Merger vested stock options granted by CGI under the 2008 and 2011 Plans are deemed to have been exchanged for equity awards of the Company. The exchange of StemoniX stock options for options to purchase Company common stock was accounted for as a modification of the StemoniX stock options; however, the modification did not result in any incremental compensation expense as the modification did not increase the fair value of the stock options. For StemoniX stock options issued prior to the Merger, the expected volatility was estimated based on the average historical volatility of similar entities with publicly traded shares as StemoniX’s shares historically were not publicly traded and its shares rarely traded privately. For common stock options granted at the time of the Merger, the Company used Vyant Bio’s historical volatility to determine the expected volatility of post-Merger option grants. Subsequently, the Company used a comparable public company group to estimate the anticipated volatility of the Company’s stock. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve at the date of grant. The Company uses a simplified method to determine the expected term for the valuation of employee options. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore, the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to options with service conditions. For options granted to nonemployees, the contractual term is used for the valuation of the options. As of December 31, 2022, there were 533,495 Schedule of Assumptions for Stock Option Grants 2022 2021 Valuation assumptions Expected dividend yield 0.0 % 0.0 % Expected volatility 56.3% 70.72% 69.5 123 % Expected term (years) – simplified method 3.0 6.1 5.5 6.1 Risk-free interest rate 1.74% 3.20 % 0.95 1.39 % Stock option activity during years ended December 31, 2022 and 2021 is as follows: Schedule of Stock Option Activity Number of Options Weighted average exercise price Weighted average remaining contractual term Balance as of January 1, 2021 151,147 $ 9.10 8.7 Granted 307,988 21.05 StemoniX options exchanged for Vyant Bio options (136,276 ) 9.20 Vyant Bio options issued to StemoniX option holders 174,652 7.20 Options assumed in Merger 11,168 229.75 Exercised (7,419 ) 6.05 Forfeited (34,462 ) 18.45 Expired (2,777 ) 9.60 Balance as of December 31, 2021 464,021 $ 20.95 8.6 Exercisable as of December 31, 2021 127,119 $ 27.90 7.1 Balance as of January 1, 2022 464,021 $ 20.95 8.6 Granted 148,855 5.02 Exercised (1,034 ) 4.80 Forfeited (141,306 ) 17.64 Expired (42,235 ) 36.33 Balance as of December 31, 2022 428,301 $ 14.97 7.5 Exercisable as of December 31, 2022 232,175 $ 18.18 6.4 The weighted average grant-date fair value of options granted during the years ended December 31, 2022 and 2021 were $ 10.23 and $ 17.55 , respectively. The Company recognized stock-based compensation in continuing operations related to different instruments for the years ended December 31, as follows: Schedule of Share Based Compensation Activity 2022 2021 December 31, 2022 2021 Stock options $ 782 $ 973 Shares issued for services 404 30 Total $ 1,186 $ 1,003 Share based compensation $ 1,186 $ 1,003 As of December 31, 2022, there was $ 1.6 2.2

Segment Information and Risk Co

Segment Information and Risk Concentration	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information and Risk Concentration	Note 14. Segment Information and Risk Concentration The Company reports segment information based on how the Company’s chief operating decision maker (“CODM”) regularly reviews operating results, allocates resources and makes decisions regarding business operations. For segment reporting purposes, the Company’s business structure is comprised of one operating and reportable segment. During both years ended December 31, 2022 and 2021, four customers and 77% 47% During years ended December 31, 2022 and 2021, approximately 47% 21% Customers representing 10% or more of the Company’s total revenue from continuing operations for years ended December 31, 2022 and 2021, are presented in the table below: Schedule of Customers Representing Revenues December 31, 2022 2021 Customer A 42 % 18 % Customer B 10 % 9 % Customer C 4 % 11 % Customer D 15 % 1 % Customer E 10 % 6 % Customer N/A 19 %

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 15. Related Party Transactions In 2020, the Company raised approximately $ 1.5 3.9 28,778 29.5295 During the fourth quarter of 2021, the Company paid a third-party collaboration partner $ 89 thousand as a reimbursement of third-party costs incurred by the collaborator in connection with the collaboration arrangement. In September 2021, an executive’s family member became an employee of this collaborator. Separately, in the fourth quarter of 2021, the Company entered into a $ 60 thousand consulting agreement with this third-party collaborator. During the first quarter of 2022, the Company paid the third-party collaboration partner $ 39 As disclosed in Note 3, the Company sold RDDT a vivo vivo

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	Note 16. Contingencies and Commitments We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business. Australian Adult Clinical Trial: vivo 3.9 million Australian dollars and can be cancelled with 60 days’ notice. This clinical trial was suspended in January 2023 as the Company evaluates its strategic alternatives.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through March 31, 2023, the date at which the financial statements were available to be issued as follows: Continuing Operations On January 4, 2023, the Company announced that it had engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. There can be no assurance that this review process will result in any changes to the Company’s current business plans or lead to any specific action or transaction. The Company’s Board of Directors (the “Board”) approved a plan on January 31, 2023 to preserve the Company’s cash to be able to continue to pursue a satisfactory strategic alternative for the purpose of maximizing the value of the Company’s business while also having sufficient cash to adequately fund an orderly wind down of the Company’s operations (the “Cash Preservation Plan”) in the event it is unable to secure a satisfactory strategic alternative. As part of the Cash Preservation Plan, the Company implemented a reduction in force which included the Company’s former President and Chief Executive Officer, and Chief Scientific Officer. The Company will record a charge of $ 954 On March 9, 2023, the Company terminated its January 2022, San Diego office and laboratory lease agreement. The effective date of the termination is March 31, 2023. The landlord is retaining approximately $ 45 1.2 On March 7, 2023, the Company sold its equipment in its San Diego laboratory to a third party and received $ 200,000 On March 24, 2023 the Company terminated its (a) Equity Distribution Agreement, dated April 8, 2022, by and between the Company and Canaccord Genuity LLC, regarding the issue and sale, from time to time, of shares of the Company’s common stock for an aggregate offering price of up to $ 20,000,000 15,000,000 Further, on March 24, 2023, the Company filed post-effective amendments to certain of its registration statements previously filed with the SEC, including post-effective amendments to each of: (i) Registration Statement Nos. 333-249513, 333-252628, 333-239497, and 333-218229 on Form S-3; (ii) Registration Statement Nos. 333-191520, 333-191521, 333-196198, 333-205903, 333-256225 and 333-214599 on Form S-8; and (ii) Registration Statement No. 333-215284 and 333-264595 on Form S-1 (such post-effective amendments, collectively the “Post-Effective Amendments” and such registration statements, collectively the “Registration Statements”). In accordance with undertakings made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities of the Company that were registered for issuance that remain unsold at the termination of the offerings, the Company removed from registration any and all securities of the Company registered but unsold under each of the Registration Statements. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statements. On March 29, 2023, the Company entered into a commitment to renew certain expiring insurance policies for a premium of $ 1.7 Discontinuing Operations To complete the disposition of the Company’s former vivo vivo vivo vivo 200 vivo vivo

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation
Segment reporting	Segment reporting vivo vivo vivo vivo vivo
Principles of consolidation	Principles of consolidation
Foreign currency	Foreign currency : The Company translates the financial statements of its foreign subsidiaries, which have a functional currency in the respective country’s local currency, to U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue, costs and expenses. Translation gains and losses are recorded in accumulated comprehensive loss as a component of stockholders’ equity. For the years ended December 31, 2022 and 2021 there were foreign currency translation gains of $ 42 74 thousand, respectively, all related to the vivo
Use of estimates	Use of estimates vivo
Risks and uncertainties	Risks and uncertainties
Cash and cash equivalents	Cash and cash equivalents 8.6 12.0
Revenue recognition	Revenue recognition The Company’s primary sources of revenue are product sales from the sale of microOrgan® plates and the performance of preclinical drug testing services using the microOrgan technology. The Company does not act as an agent in any of its revenue arrangements. For product contracts, revenue is recognized at a point-in-time upon delivery to the customer, which is generally deemed to occur upon shipment. Product contracts with customers generally state the terms of the sale, including the quantity and price of each product purchased. Payment terms and conditions may vary by contract, although terms generally include a requirement of payment within a range of 30 to 90 days after the performance obligation has been satisfied. As a result, the contracts do not include a significant financing component. In addition, contacts typically do not contain variable consideration as the contracts include stated prices. The Company provides assurance-type warranties on all of its products, which are not separate performance obligations. For service contracts, revenue is recognized over time and is generally defined pursuant to an enforceable right to payment for performance completed on service projects for which the Company has no alternative use as customer furnished compounds are added to Company plates for testing. The Company does not obtain control of the customer furnished compounds as the Company does not have the ability to direct their use. Revenue is measured by the costs incurred to date relative to the estimated total direct costs to fulfill each contract (cost-to-cost method). Incurred costs represent work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, materials and overhead. Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced or paid by the Company’s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Company’s revenue recognition criteria described above. The Company records all amounts collected for shipping as revenue. Amounts collected from customers for sales tax are recorded in sales net of amounts paid to related taxing authorities. The Company may include subcontractor or third-party vendors in certain integrated services arrangements. In these arrangements, revenue from sales of third-party vendor services is generally recorded gross as revenue and cost of goods sold - service, as the Company is the principal for the transaction. When the Company is acting as an agent between a customer and the vendor services, the Company does not record revenue and vendor costs are recorded net within cost of goods sold - service. To determine whether the Company is an agent or principal, the Company considers whether it obtains control of services before they are transferred to the customer. In making this evaluation, several factors are considered, most notably whether the Company has primary responsibility for fulfillment to the client, as well as fiscal risk and pricing discretion. There were no contract assets from continuing operations as of December 31, 2022. There were contract assets from continuing operations of $ 70 thousand as of December 31, 2021. Contract liabilities from continuing operations related to unfulfilled performance obligations were $ 72 74 75 43 1.9
Trade accounts receivable	Trade accounts receivable No
Other receivables	Other receivables 252 100 252 205
Concentration of credit risk	Concentration of credit risk : Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade receivables. The Company places cash and cash equivalents in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. As of December 31, 2022 and 2021, one and four customers, respectively, represented 10% or more of the Company’s total trade accounts receivable, and in the aggregate, these customers represented 100 %, or $ 71 78 %, or $ 262 thousand, respectively, of the Company’s total trade accounts receivable.
Inventory	Inventory
Prepaid expenses and other assets	Prepaid expenses and other assets 2.7 , 797 1.0
Deferred revenue	Deferred revenue
Fixed assets	Fixed assets The estimated useful life of equipment is five years Long-lived assets, such as fixed assets subject to depreciation, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If circumstances require a long-lived asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset group to its carrying amount. If the carrying amount of the long-lived asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. As of December 31, 2022 and 2021 the Company determined that there were no indicators of impairment and did not recognize any fixed asset impairment use in continuing operations.
Goodwill	Goodwill 22.4 vivo vivo 20.2 2.2
Convertible notes	Convertible notes
Fair value option	Fair value option
Warrants	Warrants The Company issued a warrant during first quarter of 2021 that contained an indexation feature not indexed to the Company’s stock resulting in this warrant being accounted for as a derivative. Derivative warrants are recorded as liabilities in the accompanying consolidated balance sheets. These common stock purchase warrants do not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using the Black-Scholes valuation pricing model with the assumptions as follows: the risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. The Company uses the historical volatility of its common stock and the closing price of its shares on the NASDAQ Capital Market. As further described in Note 10 to the consolidated financial statements, as a result of the Merger, the terms of this warrant were finalized through the conversion to a Vyant Bio warrant resulting in the Vyant Bio warrant being equity classified.
Derivative instruments	Derivative instruments
Income taxes	Income taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits and penalties in income tax expense. The Company elects to present deferred taxes and the effect of unrecognized tax benefits associated with the held for sale assets and liabilities as part of the assets (or liabilities) held for sale. The deferred taxes primarily relate to net operating loss carryforwards in US and foreign jurisdictions that are classified as held for sale. Due to a valuation allowance recorded against the deferred tax assets, the net impact of deferred tax assets included in the held for sale assets and liabilities is $ 0
Leases	Leases For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company has elected the practical expedient to account for lease and non-lease components as a single lease component. Therefore, the lease payments used to measure the lease liability includes all of the fixed consideration in the contract. Key estimates and judgments include how the Company determines (1) the discount rate it uses to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. The Company discounts its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Generally, the Company cannot determine the interest rate implicit in the lease because it does not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company generally uses its incremental borrowing rate as the discount rate for the lease. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company does not generally borrow on a collateralized basis, it uses the interest rate it pays on its non-collateralized borrowings as an input to deriving an appropriate incremental borrowing rate, adjusted for the lease payments, the lease term and the effect on that rate of designating specific collateral with a value equal to the unpaid lease payments for that lease. The lease term for all the Company’s leases includes the noncancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.
Intangible assets	Intangible assets vivo ten years vivo no 713
Research and development	Research and development 6.8 4.3
Advertising costs	Advertising costs were $ 28 34
Stock-based compensation	Stock-based compensation
Commitments and contingencies	Commitments and contingencies
Fair value measurements	Fair value measurements ● Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. ● Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Valuation of business combination	Valuation of business combination
Subsequent events	Subsequent events
Net loss per share	Net loss per share

Cancer Genetics, Inc. Merger (T

Cancer Genetics, Inc. Merger (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Preliminary Allocation of Purchase Price Consideration	The following details the allocation of the preliminary purchase price consideration recorded on March 30, 2021, the acquisition date, with adjustments recorded through the first quarter of 2022, the end of the purchase price allocation period. Schedule of Preliminary Allocation of Purchase Price Consideration Preliminary Adjustments Final Assets acquired: Cash and equivalents $ 30,163 $ - $ 30,163 Accounts receivable 705 - 705 Other current assets 806 227 1,033 Intangible assets 9,500 - 9,500 Fixed assets 416 (256 ) 160 Goodwill 22,164 216 22,380 Long-term prepaid expenses and other assets 1,381 - 1,381 Total assets acquired $ 65,135 $ 187 $ 65,322 Liabilities assumed: Accounts payable and accrued expenses $ 2,670 $ 437 $ 3,107 Current liabilities of discontinuing operations 588 (141 ) 447 Obligations under operating leases 198 - 198 Obligations under finance leases 106 - 106 Deferred revenue 1,293 (114 ) 1,179 Payroll and income taxes payable 360 5 365 Total liabilities assumed $ 5,215 $ 187 $ 5,402 Net assets acquired $ 59,920 $ - $ 59,920
Schedule of Proforma Financial Information	The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2021: Schedule of Proforma Financial Information Year ended December 31, 2021 Total revenue $ 6,726 Net loss (35,623 ) Pro forma loss per common share, (6.15 ) Pro forma weighted average number of common shares basic and diluted 5,795,498

Discontinuing Operations (Table

Discontinuing Operations (Tables)	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups Including Discontinuing Operations from Income Statement	Results of discontinuing operations were as follows: Schedule of Disposal Groups Including Discontinuing Operations from Income Statement 2022 2021 Years ended December 31, 2022 2021 Revenue $ 6,406 $ 3,978 Cost of goods sold 3,189 2,524 General and administrative 4,709 3,531 Impairment of goodwill and intangible assets 5,415 20,216 Total operating costs and expenses $ 13,313 $ 26,271 Loss from discontinuing operations $ (6,907 ) $ (22,293 ) Total other income $ 3 $ 9 Loss from discontinuing operations before income taxes $ (6,904 ) $ (22,284 ) Income tax expense (benefit) (21 ) - Net loss from discontinuing operations $ (6,883 ) $ (22,284 )
Schedule of Disposal Groups Including Discontinuing Operations from Balance Sheet	Asset and liabilities of discontinuing operations were as follows: Schedule of Disposal Groups Including Discontinuing Operations from Balance Sheet 2022 2021 December 31, 2022 2021 Accounts receivable $ 11 $ 457 Due from Reaction Biology Corporation 334 Other current assets - 345 Assets of discontinuing operations - current $ 345 $ 802 Fixed assets, net of accumulated depreciation $ - $ 163 Operating lease right-of-use assets - 30 Patents and other intangible assets, net - 8,787 Goodwill - 2,164 Other assets - 364 Assets of discontinuing operations - non-current $ - $ 11,508 Accounts payable $ 47 $ 358 Due to RDDT a vivoPharm Company Pty Ltd 216 Accrued expense 577 418 Obligation under operating lease, current - 29 Obligation under finance lease, current - 32 Deferred revenue 43 1,911 Taxes payable 69 365 Other current liabilities 267 409 Liabilities of discontinued operations - current $ 1,219 $ 3,522 Obligations under operating leases, less current $ - $ 2 Obligations under finance leases, less current - 47 Liabilities of discontinued operations -non- current $ - $ 49
Schedule of Intangible Assets	There were no Schedule of Intangible Assets 2021 Intangible Assets: Customer relationships $ 8,000 Trade name 1,500 Intangible assets gross 9,500 Less accumulated amortization (713 ) Intangible assets, net $ 8,787
Schedule of Goodwill Rollforward	Goodwill arising from the Merger was solely attributed to the vivo Schedule of Goodwill Rollforward Beginning balance, January 1, 2021 $ - Initial balance upon consummation of the Merger 22,164 Purchase price adjustments 216 Impairment charge (20,216 ) Ending balance, December 31, 2021 $ 2,164 Impairment charge (2,164 ) Ending balance, December 31, 2022 $ -

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventory consists of the following: Schedule of Inventory December 31, 2022 December 31, 2021 Finished goods $ - $ 23 Work in process 9 138 Raw materials 44 314 Total inventory $ 53 $ 475

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Presented in the table below are the major classes of fixed assets by category: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Equipment $ 2,962 $ 2,733 Furniture and fixtures 6 6 Leasehold improvements 612 251 Fixed assets, gross 3,580 2,990 Less accumulated depreciation (2,474 ) (1,970 ) Fixed assets, net $ 1,106 $ 1,020

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of Components of Lease Expense and Supplemental Information	The components of operating and finance lease expense in continuing operations for the years ended December 31, are as follows: Schedule of Components of Lease Expense and Supplemental Information 2022 2021 Operating lease cost $ 441 $ 504 Finance lease cost: Depreciation of ROU assets $ 204 $ 35 Interest on lease liabilities 34 8 Total finance lease cost: $ 238 $ 43 Variable lease costs $ - $ - Short-term lease costs - - Total lease continuing operations expense $ 679 $ 547 Supplemental cash flow related to operating and finance leases of the Company’s continuing operations is as follows for the years ended December 31, 2022 and 2021: 2022 2021 Cash paid amounts included in the measurement of lease liabilities from continuing operations: Operating cash flows used for operating leases $ (265 ) $ (509 ) Financing cash flows used for finance leases $ (191 ) $ (37 ) Financing cash flows provided by finance leases $ 266 $ 492 Other supplemental information related to operating and finance leases of the Company’s continuing operations is as follows as of December 31, 2022 and 2021: 2022 2021 Weighted average remaining lease term (in years): Operating leases 4.45 5.42 Finance leases 2.05 2.75 Weighted average discount rate: Operating leases 8.30 % 9.88 % Finance leases 6.90 % 6.54 %
Schedule of Amounts Reported in the Consolidated Balance Sheet	Amounts reported in the consolidated balance sheet from continuing operations as of December 31, 2022 and 2021 are as follows: Schedule of Amounts Reported in the Consolidated Balance Sheet 2022 2021 Operating leases: Operating lease ROU assets, net $ 1,542 $ 673 Operating lease current liabilities $ 313 $ 174 Operating lease long-term liabilities 1,301 516 Total operating lease liabilities $ 1,614 $ 690 Finance leases: Equipment $ 744 $ 477 Accumulated depreciation (244 ) (63 ) Finance leases, net $ 500 $ 414 Current installment obligations under finance leases $ 252 $ 157 Long-term portion of obligations under finance leases 273 293 Total finance lease liabilities $ 525 $ 450
Schedule of Annual Payments of Lease liabilities Under Noncancelable leases	Annual future payments of lease liabilities under noncancelable leases as of December 31, 2022 are as follows: Schedule of Annual Payments of Lease liabilities Under Noncancelable leases Operating leases Finance leases 2023 $ 433 $ 280 2024 423 235 2025 427 50 2026 441 - 2027 215 - Thereafter - - Total undiscounted lease payments 1,939 566 Less: imputed interest (325 ) (41 ) Total lease liabilities $ 1,614 $ 525

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Loss Before Income Tax From Continuing operations	The components of loss before income taxes from continuing operations consist of the following. Schedule of Components of Loss Before Income Tax From Continuing operations 2022 2021 United States $ (15,807 ) $ (18,575 ) Foreign - - Total loss before income taxes $ (15,807 ) $ (18,575 )
Schedule of Components of Income Tax Expense Benefit	The Company did not record any current, deferred, or net income tax expense (benefit) from continuing operations in 2022 or 2021. Total income tax expense (benefit) from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% Schedule of Components of Income Tax Expense Benefit 2022 2021 Computed “expected” tax expense $ (3,219 ) $ (3,901) Deferred rate change (132 ) 84 State taxes, net of federal tax effect (822 ) (752) Non-deductible transaction costs - 222 Non-deductible interest 2 664 R&D tax credit 238 (238) Sale of vivo Pharm business (72 ) Other, net 117 (51) Change in valuation allowance 3,888 3,972 Income tax expense (benefit) $ - $ -
Components of Approximate Deferred tax	The tax effects of temporary differences from continuing operations that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below as of December 31: Components of Approximate Deferred tax 2022 2021 Deferred tax assets Accrued liabilities $ 109 $ 47 Capitalized R&D costs 3,233 1,931 Intangibles 107 127 Fixed assets 2 - Stock compensation 248 160 Lease liability 478 170 Loss carryforward 20,750 18,144 Tax credit carryforward 1,085 1,406 Other temporary differences 3 4 Total gross deferred tax assets 26,015 21,989 Valuation allowance (25,614 ) (21,807 ) Total deferred tax assets $ 401 $ 182 Deferred tax liabilities Fixed assets $ - $ (17 ) Lease assets (401 ) (165 ) Total gross deferred tax liabilities $ (401 ) $ (182 ) Net deferred tax asset $ - $ -

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long- term Debt	Long-term debt consists of the following: Schedule of Long- term Debt December 31, December 31, Economic Injury Disaster Loan $ 57 $ 57 Total long-term debt $ 57 $ 57
Schedule of Future Annual Principal Repayments Due on Long - term Debt	Future annual principal repayments due on the long-term debt as of December 31, 2022 are as follows: Schedule of Future Annual Principal Repayments Due on Long - term Debt Amount 2023 $ 1 2024 1 2025 1 2026 1 2027 1 Thereafter 52 Total $ 57

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Common Stock Warrants Outstanding	Summary of Common Stock Warrants Outstanding Issuance Related to: Exercise Price Outstanding Warrants Expiration Dates 2020 Convertible Note $ 29.55 28,778 Feb 23, 2026 2021 offerings $ 17.50 324,828 Feb 10, 2026 - Aug 3, 2026 Advisory fees $ 12.10 37.95 98,578 Jan 9, 2024 - Oct 28, 2025 Debt $ 138.00 2,955 Mar 22, 2024 Total 455,139

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Changes in Fair Value of Level 3 Valued Instruments	The following tables present changes in fair value of level 3 valued instruments as of and for the years ended December 31, 2022 and 2021: Schedule of Changes in Fair Value of Level 3 Valued Instruments vivo Balance - January 1, 2022 $ 11,000 Additions - Measurement adjustments (5,528 ) Sale of vivo (5,472 ) Balance - December 31, 2022 $ - The following tables present changes in fair value of level 3 valued instruments for the year ended December 31, 2021: 2020 Convertible Note Warrant Embedded Derivative vivo Balance - January 1, 2021 $ - $ - $ 1,690 $ - Additions 3,746 635 325 11,000 Measurement adjustments 4 (214 ) 250 - Settlement (3,750 ) (421 ) (2,265 ) - Balance - December 31, 2021 $ - $ - $ - $ 11,000

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share	Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted loss per share calculations for the years ended December 31, 2022 and 2021: Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share 2022 2021 December 31, 2022 2021 Net loss from continuing operations $ (15,807 ) $ (18,575 ) Net loss from discontinuing operations (6,883 ) (22,284 ) Net loss $ (22,690 ) $ (40,859 ) Basic and diluted weighted average shares outstanding 5,868,402 4,522,889 Basic and diluted net loss per share: Continuing operations $ (2.69 ) $ (4.11 ) Discontinuing operations (1.18 ) (4.92 ) Net loss $ (3.87 ) $ (9.03 )
Schedule of Computation of Diluted Shares Outstanding	The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2022 and 2021 because the effect would be anti-dilutive: Schedule of Computation of Diluted Shares Outstanding December 31, 2022 2021 Common Stock warrants 455,139 459,382 Common Stock options 428,301 464,019 Restricted stock 77,104 - Total 960,544 923,401 Anti-dilutive securities 960,544 923,401

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions for Stock Option Grants	Schedule of Assumptions for Stock Option Grants 2022 2021 Valuation assumptions Expected dividend yield 0.0 % 0.0 % Expected volatility 56.3% 70.72% 69.5 123 % Expected term (years) – simplified method 3.0 6.1 5.5 6.1 Risk-free interest rate 1.74% 3.20 % 0.95 1.39 %
Schedule of Stock Option Activity	Stock option activity during years ended December 31, 2022 and 2021 is as follows: Schedule of Stock Option Activity Number of Options Weighted average exercise price Weighted average remaining contractual term Balance as of January 1, 2021 151,147 $ 9.10 8.7 Granted 307,988 21.05 StemoniX options exchanged for Vyant Bio options (136,276 ) 9.20 Vyant Bio options issued to StemoniX option holders 174,652 7.20 Options assumed in Merger 11,168 229.75 Exercised (7,419 ) 6.05 Forfeited (34,462 ) 18.45 Expired (2,777 ) 9.60 Balance as of December 31, 2021 464,021 $ 20.95 8.6 Exercisable as of December 31, 2021 127,119 $ 27.90 7.1 Balance as of January 1, 2022 464,021 $ 20.95 8.6 Granted 148,855 5.02 Exercised (1,034 ) 4.80 Forfeited (141,306 ) 17.64 Expired (42,235 ) 36.33 Balance as of December 31, 2022 428,301 $ 14.97 7.5 Exercisable as of December 31, 2022 232,175 $ 18.18 6.4
Schedule of Share Based Compensation Activity	The Company recognized stock-based compensation in continuing operations related to different instruments for the years ended December 31, as follows: Schedule of Share Based Compensation Activity 2022 2021 December 31, 2022 2021 Stock options $ 782 $ 973 Shares issued for services 404 30 Total $ 1,186 $ 1,003 Share based compensation $ 1,186 $ 1,003

Segment Information and Risk _2

Segment Information and Risk Concentration (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Customers Representing Revenues	Customers representing 10% or more of the Company’s total revenue from continuing operations for years ended December 31, 2022 and 2021, are presented in the table below: Schedule of Customers Representing Revenues December 31, 2022 2021 Customer A 42 % 18 % Customer B 10 % 9 % Customer C 4 % 11 % Customer D 15 % 1 % Customer E 10 % 6 % Customer N/A 19 %

Organization, Description of _2

Organization, Description of Business, Business Disposals, Offerings and Merger (Details Narrative) - USD ($)				12 Months Ended
	Mar. 24, 2023	Apr. 08, 2022	Mar. 28, 2022	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents				$ 10,041,000	$ 20,608,000
Accumulated deficit				101,503,000	78,813,000
Net cash used in operating activities, continuing operations				12,888,000	16,488,000
Loss from continuing operations before income taxes				15,807,000	18,575,000
Loss from continuing operations				$ 15,807,000	$ 18,575,000
Equity Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price	$ 20,000,000
Equity Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price		$ 20,000,000
Equity Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Maximum [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price	20,000,000
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price	15,000,000
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price			$ 15,000,000
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price	$ 15,000,000

Schedule of Preliminary Allocat

Schedule of Preliminary Allocation of Purchase Price Consideration (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Mar. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 2,164
StemoniX [Member]
Business Acquisition [Line Items]
Cash and equivalents	30,163		$ 30,163
Accounts receivable	705		705
Other current assets	1,033		806
Intangible assets	9,500		9,500
Fixed assets	160		416
Goodwill	22,380		22,164
Long-term prepaid expenses and other assets	1,381		1,381
Total assets acquired	65,322		65,135
Accounts payable and accrued expenses	3,107		2,670
Current liabilities of discontinuing operations	447		588
Obligations under operating leases	198		198
Obligations under finance leases	106		106
Deferred revenue	1,179		1,293
Payroll and income taxes payable	365		360
Total liabilities assumed	5,402		5,215
Net assets acquired	59,920		$ 59,920
StemoniX [Member] | Revision of Prior Period, Adjustment [Member]
Business Acquisition [Line Items]
Cash and equivalents
Accounts receivable
Other current assets	227
Intangible assets
Fixed assets	(256)
Goodwill	216
Long-term prepaid expenses and other assets
Total assets acquired	187
Accounts payable and accrued expenses	437
Current liabilities of discontinuing operations	(141)
Obligations under operating leases
Obligations under finance leases
Deferred revenue	(114)
Payroll and income taxes payable	5
Total liabilities assumed	187
Net assets acquired

Schedule of Proforma Financial

Schedule of Proforma Financial Information (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares
Business Combination and Asset Acquisition [Abstract]
Total revenue	$ 6,726
Net loss	$ (35,623)
Pro forma loss per common share, | $ / shares	$ (6.15)
Pro forma weighted average number of common shares basic and diluted | shares	5,795,498

Cancer Genetics, Inc. Merger (D

Cancer Genetics, Inc. Merger (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Mar. 30, 2021	Aug. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Feb. 23, 2021
Business Acquisition [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.0001	$ 0.0001
Business combination, acquisition related costs				$ 2,310
Estimated useful life			10 years
Revenue percentage description			Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues			121,000
StemoniX [Member]
Business Acquisition [Line Items]
Intangible assets related to Merger, recognized	$ 9,500		$ 9,500
StemoniX [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	160,942
Business combination consideration transferred	$ 59,900
StemoniX [Member] | Merger Agreement [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	2,201,437
Business combination, step acquisition, equity interest in acquiree, fair value	$ 50,740
StemoniX [Member] | Merger Agreement [Member] | Common Stock Warrants [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	431,537
Business combination, step acquisition, equity interest in acquiree, fair value	$ 9,040
StemoniX [Member] | Merger Agreement [Member] | Common Stock Options [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	11,181
Business combination, step acquisition, equity interest in acquiree, fair value	$ 139
StemoniX [Member] | Holders [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues		3,595,508
Common Stock, Par or Stated Value Per Share		$ 0.0001
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award		178,356
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit		$ 3.30
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit		$ 23.05
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award		28,778
Shares Issued, Price Per Share		$ 29.5295	$ 29.5295		$ 29.5295
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Business combination, acquisition related costs				$ 2,300
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets related to Merger, recognized			$ 1,500
Estimated useful life			10 years
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets related to Merger, recognized			$ 8,000
Royalty payment percentage			1%

Schedule of Disposal Groups Inc

Schedule of Disposal Groups Including Discontinuing Operations from Income Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 6,406	$ 3,978
Cost of goods sold	3,189	2,524
General and administrative	4,709	3,531
Impairment of goodwill and intangible assets	5,415	20,216
Total operating costs and expenses	13,313	26,271
Loss from discontinuing operations	(6,907)	(22,293)
Total other income	3	9
Loss from discontinuing operations before income taxes	(6,904)	(22,284)
Income tax expense (benefit)	(21)
Net loss from discontinuing operations	$ (6,883)	$ (22,284)

Schedule of Disposal Groups I_2

Schedule of Disposal Groups Including Discontinuing Operations from Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Accounts receivable	$ 11	$ 457
Due from Reaction Biology Corporation	334
Other current assets		345
Assets of discontinuing operations - current	345	802
Fixed assets, net of accumulated depreciation		163
Operating lease right-of-use assets		30
Patents and other intangible assets, net		8,787
Goodwill		2,164
Other assets		364
Assets of discontinuing operations - non-current		11,508
Accounts payable	47	358
Due to RDDT a vivoPharm Company Pty Ltd	216
Accrued expense	577	418
Obligation under operating lease, current		29
Obligation under finance lease, current		32
Deferred revenue	43	1,911
Taxes payable	69	365
Other current liabilities	267	409
Liabilities of discontinued operations - current	1,219	3,522
Obligations under operating leases, less current		2
Obligations under finance leases, less current		47
Liabilities of discontinued operations -non- current		$ 49

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 0	$ 8,787,000
Intangible assets gross		9,500,000
Less accumulated amortization		(713,000)
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets gross		8,000,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets gross		$ 1,500,000

Schedule of Goodwill Rollforwar

Schedule of Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Beginning balance	$ 2,164
Beginning balance		22,164
Beginning balance		216
Beginning balance	(2,164)	(20,216)
Beginning balance		$ 2,164

Discontinuing Operations (Detai

Discontinuing Operations (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 02, 2022	Feb. 28, 2023	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 30, 2022
Disposal Group, Including Discontinued Operation, Assets							$ 2,000,000
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents							$ 827
Impairment of intangible assets, indefinite-lived			$ 1,500,000	$ 20,200,000	$ 5,400,000
Liabilities of discontinuing operations - current				3,522,000	1,219,000	$ 3,522,000
Amortization of intangible assets					0	713,000
Cancer Genetics Inc [Member]
Liabilities of discontinuing operations - current				$ 409,000	267,000	$ 409,000
Trade Names [Member]
Impairment of intangible assets, indefinite-lived					500,000
Customer Relationships [Member]
Impairment of intangible assets, indefinite-lived					2,700,000
Goodwill [Member]
Impairment of intangible assets, indefinite-lived					$ 2,200,000
Vivo Pharm Pty Ltd [Member]
Gain (Loss) on Disposition of Assets	$ 5,500,000
[custom:GainLossOnDispositionOfAssetsAdjustment]	5,500,000
Disposal Group, Including Discontinued Operation, Assets	4,800,000
Business Exit Costs	400,000
Disposal Group, Including Discontinued Operation, Liabilities	$ 357,000
Vivo Pharm Pty Ltd [Member] | Subsequent Event [Member]
[custom:GainLossOnDispositionOfAssetsAdjustment]		$ 300,000

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ 42,000	$ 74,000
Cash and Cash equivalents	10,041,000	20,608,000
Contract assets from continuing operations	0	70,000
Contract liabilities from continuing operations	72,000	74,000
Contract with customer discontinued		75,000
Contract with customer liability current discontinued operation	43,000	1,900,000
Accounts receivable, allowance for credit loss, current	0	0
Prepaid expense	$ 797,000	1,000,000
Estimated useful life	The estimated useful life of equipment is five years
Goodwill		2,164,000
Goodwill impairment	2,164,000	20,216,000
Net deferred tax asset
Estimated useful lives of assets	10 years
Intangible assets remaining	$ 0	8,787,000
Amortization of Intangible Assets	0	713,000
Research and development expense	6,772,000	4,273,000
Advertising costs	28,000	34,000
Vivo Pharm [Member]
Product Information [Line Items]
Goodwill	22,400,000
Vivo Pharm Pty Ltd [Member]
Product Information [Line Items]
Goodwill impairment	2,200,000	$ 20,200,000
Directors and Officers [Member]
Product Information [Line Items]
Premiums receivable	$ 2,700,000
Three Customers [Member] | Trade Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	100%
Accounts receivable net	$ 71,000
Four Customers [Member] | Trade Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage		78%
Accounts receivable net		$ 262,000
Research and Development Expense [Member]
Product Information [Line Items]
Other Receivables	252,000	100,000
Reduction in payroll tax expenses	252,000	205,000
Money Market Funds [Member]
Product Information [Line Items]
Cash and Cash equivalents	$ 8,600,000	$ 12,000,000

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods		$ 23
Work in process	9	138
Raw materials	44	314
Total inventory	$ 53	$ 475

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 3,580	$ 2,990
Less accumulated depreciation	(2,474)	(1,970)
Fixed assets, net	1,106	1,020
Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	2,962	2,733
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	6	6
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 612	$ 251

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 522	$ 550

Schedule of Components of Lease

Schedule of Components of Lease Expense and Supplemental Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease cost	$ 441	$ 504
Depreciation of ROU assets	204	35
Interest on lease liabilities	34	8
Total finance lease cost:	238	43
Variable lease costs
Short-term lease costs
Total lease continuing operations expense	679	547
Operating Lease, Payments	(265)	(509)
Finance Lease, Principal and Interest Payments	(191)	(37)
Financing cash flows provided by finance leases.	$ 266	$ 492
Operating lease, weighted average remaining lease term	4 years 5 months 12 days	5 years 5 months 1 day
Finance leaseweighted average remaining lease term	2 years 18 days	2 years 9 months
Operating lease, weighted average discount rate, percent	8.30%	9.88%
Finance leaseweighted average discount rate, percent	6.90%	6.54%

Schedule of Amounts Reported in

Schedule of Amounts Reported in the Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2021
Leases
Operating lease ROU assets, net	$ 1,542	$ 1,200	$ 673
Operating lease current liabilities	313		174
Operating lease long-term liabilities	1,301		516
Total operating lease liabilities	1,614	$ 1,200	690
Equipment	744		477
Accumulated depreciation	(244)		(63)
Finance leases, net	500		414
Current installment obligations under finance leases	252		157
Long-term portion of obligations under finance leases	273		293
Total finance lease liabilities	$ 525		$ 450

Schedule of Annual Payments of

Schedule of Annual Payments of Lease liabilities Under Noncancelable leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, to be Paid [Abstract]
Operating lease - 2023	$ 433
Operating lease - 2023	423
Operating lease - 2023	427
Operating lease - 2023	441
Operating lease - 2023	215
Operating lease - 2023
Operating lease - 2023	1,939
Operating lease - 2023	(325)
Operating lease - 2023	1,614	$ 1,200	$ 690
Finance Lease, Liability, to be Paid [Abstract]
Finance leases - 2023	280
Finance leases - 2023	235
Finance leases - 2023	50
Finance leases - 2023
Finance leases - 2023
Finance leases - 2023
Finance leases - 2023	566
Finance leases - 2023	(41)
Finance leases - 2023	$ 525		$ 450

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Oct. 31, 2021	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Apr. 01, 2021
Property, Plant and Equipment [Line Items]
Lessee finance lease description		As of December 31, 2022, the Company leased facilities in Maple Grove, Minnesota and in San Diego, California under arrangements which expire in
Operating lease, right-of-use asset		$ 1,542	$ 1,200	$ 673
Operating lease obligation		$ 1,614	$ 1,200	$ 690
Laboratory Research and Administrative Office [Member]
Property, Plant and Equipment [Line Items]
Operating lease, right-of-use asset					$ 83
Operating lease obligation					$ 83
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment financing lease	$ 491

Schedule of Components of Loss

Schedule of Components of Loss Before Income Tax From Continuing operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total loss before income taxes	$ (15,807)	$ (18,575)
UNITED STATES
Total loss before income taxes	(15,807)	(18,575)
Non-US [Member]
Total loss before income taxes

Schedule of Components of Incom

Schedule of Components of Income Tax Expense Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Computed “expected” tax expense		$ (3,901)
Deferred rate change		84
State taxes, net of federal tax effect		(752)
Non-deductible transaction costs		222
Non-deductible interest		664
R&D tax credit		(238)
Other, net		(51)
Change in valuation allowance		3,972
Income tax expense (benefit)

Components of Approximate Defer

Components of Approximate Deferred tax (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Accrued liabilities	$ 109	$ 47
Capitalized R&D costs	3,233	1,931
Intangibles	107	127
Fixed assets	2
Stock compensation	248	160
Lease liability	478	170
Loss carryforward	20,750	18,144
Tax credit carryforward	1,085	1,406
Other temporary differences	3	4
Total gross deferred tax assets	26,015	21,989
Valuation allowance	(25,614)	(21,807)
Total deferred tax assets	401	182
Deferred tax liabilities
Fixed assets	0	(17)
Lease assets	(401)	(165)
Total gross deferred tax liabilities	(401)	(182)
Net deferred tax asset

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Aug. 16, 2022	Jan. 02, 2018	Dec. 31, 2017
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Federal income tax rate	21%
Operating Loss Carryforwards	$ 78.3			$ 66.4
Percentage of excise tax corporate stock repurchases		1%
Between Two Thousand And Twenty Six And Two Thousand And Thirty Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Operating Loss Carryforwards			$ 11.9

Schedule of Long- term Debt (De

Schedule of Long- term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total long-term debt	$ 57	$ 57
Economic Injury Disaster Loan [Member]
Debt Instrument [Line Items]
Total long-term debt before debt issuance costs and debt discount	$ 57	$ 57

Schedule of Future Annual Princ

Schedule of Future Annual Principal Repayments Due on Long - term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2023	$ 1
2024	1
2025	1
2026	1
2027	1
Thereafter	52
Total	$ 57	$ 57

Long-Term Debt (Details Narrati

Long-Term Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

Feb. 23, 2021

Feb. 08, 2021

Aug. 21, 2020

Aug. 21, 2020

Apr. 30, 2020

Mar. 12, 2021

Mar. 31, 2022

Dec. 31, 2021

Mar. 31, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Feb. 21, 2021

May 04, 2020

Debt Instrument [Line Items]

Additional shares issued in cancellation

$ (192)

Proceeds from convertible debt

$ 5,022

Payments to related parties

$ 39

$ 89

Loss on debt extinguishment

$ 2,500

Merger Agreement [Member]

Debt Instrument [Line Items]

Warrants to purchase common stock

28,778

StemoniX [Member] | Investor [Member] | Merger Agreement [Member]

Debt Instrument [Line Items]

Warrants to purchase common stock

28,778

28,778

Warrant exercise price per share

$ 29.5295

$ 29.5295

$ 29.5295

$ 29.5295

StemoniX [Member] | Convertible Notes [Member] | Investor [Member] | Merger Agreement [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 3,000

$ 1,250

2020 Convertible Notes [Member]

Debt Instrument [Line Items]

Convertible debt

10,000

$ 3,000

Proceeds from convertible debt

$ 5,000

$ 3,900

$ 1,500

Debt conversion modified discount description

For any Major Investor, the modified terms provide for a fixed conversion discount on the 2020 Convertible Notes of 20% and a common stock warrant equal to 20% of the amount invested in all 2020 Convertible Notes by such Major Investor divided by the weighted average share price of the Common Stock over the five trading days prior to the closing of the Merger

2020 Convertible Notes [Member] | Merger Agreement [Member]

Debt Instrument [Line Items]

Outstanding principal amount

$ 12,700

Accrued interest

$ 468

Exchange shares issued

667,788

Debt, weighted average interest rate

18.22%

18.22%

2020 Convertible Notes [Member] | StemoniX [Member]

Debt Instrument [Line Items]

Payments to related parties

$ 3,900

2020 Convertible Notes [Member] | Series B Preferred Stock [Member]

Debt Instrument [Line Items]

Additional shares issued in cancellation

$ 3,900

2020 Convertible Notes [Member] | Maximum [Member]

Debt Instrument [Line Items]

Convertible debt

$ 10,000

Paycheck Protection Program [Member]

Debt Instrument [Line Items]

Proceeds from loans

$ 730

Loan forgiveness

$ 730

Economic Injury Disaster Loan [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 57

Debt Instrument, Interest Rate, Effective Percentage

3.75%

Debt Instrument, Payment Terms

repayable in monthly installments starting in June 2022

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Outstanding Warrants | shares	455,139
2020 Convertible Note [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 29.55
Outstanding Warrants | shares	28,778
Warrants maturity date description	Feb. 23, 2026
2021 Offering [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 17.50
Outstanding Warrants | shares	324,828
Warrants maturity date description	Feb 10, 2026 - Aug 3, 2026
Advisory Fees [Member]
Class of Warrant or Right [Line Items]
Outstanding Warrants | shares	98,578
Warrants maturity date description	Jan 9, 2024 - Oct 28, 2025
Advisory Fees [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 12.10
Advisory Fees [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	37.95
Debt One [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 138
Outstanding Warrants | shares	2,955
Warrants maturity date description	Mar. 22, 2024

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					3 Months Ended	12 Months Ended
	Dec. 31, 2022	Apr. 08, 2022	Mar. 28, 2022	Mar. 15, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 21, 2021
Class of Stock [Line Items]
Preferred stock, shares outstanding	0					0	0
Preferred stock, shares authorized	9,764,000					9,764,000	9,764,000
Fair value of warrants							$ (214,000)
Warrant and rights assumed	431,537					431,537
Warrants and rights outstanding	455,139					455,139
Cancer Genetics Inc Merger [Member]
Class of Stock [Line Items]
Warrants and rights outstanding	426,361					426,361
Preferred Stock Warrants [Member]
Class of Stock [Line Items]
Conversion of warrants into stock						8,621
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding								4,611,587
Shares exchanged for common stock								5,973,509
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding								3,489,470
Shares exchanged for common stock								4,524,171
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs							$ 214,000
Shares exchanged for common stock						699,395
Stock issued during period, value, conversion of convertible securities				$ 2,000,000
Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs						$ 250,000
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			81,190
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member]
Class of Stock [Line Items]
Aggregate offering price			$ 15,000,000
Equity Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Maximum [Member]
Class of Stock [Line Items]
Aggregate offering price		$ 20,000,000
Sales Agreement [Member] | Canaccord Genuity LLC [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	41,162
Merger Agreement [Member]
Class of Stock [Line Items]
Number of warrants issued									28,778
Warrants exercise price									$ 29.5295
Fair value of warrants					$ 214,000
Merger Agreement [Member] | Investor Warrant [Member]
Class of Stock [Line Items]
Fair value of warrants						$ 421,000

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Additions		$ (250)
2020 Convertible Note [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance
Additions		3,746
Measurement adjustments		4
Settlement		(3,750)
Ending Balance
Warrants [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance
Additions		635
Measurement adjustments		(214)
Settlement		(421)
Ending Balance
Embedded Derivative [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance		1,690
Additions		325
Measurement adjustments		250
Settlement		(2,265)
Ending Balance
Vivo Pharm Pty Ltd [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance	11,000
Additions		11,000
Measurement adjustments	(5,528)
Settlement	(5,472)
Ending Balance		$ 11,000

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) $ / shares in Units, $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Mar. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
[custom:DecreaseInFairValueMeasurement-0]			$ 4,500
[custom:ImpairmentCharge]			$ 4,300
Net of estimated disposal costs	$ 4,900			$ 9,200	$ 4,900
Asset Impairment Charges		$ 1,500		$ 20,200	5,400
Fair Value, Net Asset (Liability)	388				$ 388
Gain (Loss) on Sales of Loans, Net	$ 106
2020 Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants exercise price per share | $ / shares	$ 2.01				$ 2.01
Warrants term	5 years				5 years
2020 Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.59				0.59
2020 Convertible Notes [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.86				0.86
2020 Convertible Notes [Member] | Series B Convertible Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt conversion and discount description					The instrument provided the holder the right to convert the instrument into shares of Series B Preferred Stock at a 20% discount. Given the timing of the issuance of the instrument near the Merger date, management determined that there was a 99.5% probability of the holders converting the instrument to Company shares at a 20% discount
2020 Convertible Notes [Member] | Investor [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investment in debt						$ 3,000

Schedule of Reconciliation of N

Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss from continuing operations	$ (15,807)	$ (18,575)
Net loss from discontinuing operations	(6,883)	(22,284)
Net loss	$ (22,690)	$ (40,859)
Basic and diluted weighted average shares outstanding	5,868,402	4,522,889
Basic and diluted net loss per share:
Continuing operations	$ (2.69)	$ (4.11)
Discontinuing operations	(1.18)	(4.92)
Net loss	$ (3.87)	$ (9.03)

Schedule of Computation of Dilu

Schedule of Computation of Diluted Shares Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	960,544	923,401
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	455,139	459,382
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	428,301	464,019
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	77,104

Schedule of Assumptions for Sto

Schedule of Assumptions for Stock Option Grants (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	0%	0%
Expected volatility, minimum	56.30%	69.50%
Expected volatility, maximum	70.72%	123%
Risk-free interest rate, minimum	1.74%	0.95%
Risk-free interest rate, maximum	3.20%	1.39%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term years simplified method	3 years	5 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term years simplified method	6 years 1 month 6 days	6 years 1 month 6 days

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Number of Options, Beginning Balance	464,021	151,147
Weighted average exercise price, Beginning Balance	$ 20.95	$ 9.10
Weighted average remaining contractual term, Ending Balance	7 years 6 months	8 years 7 months 6 days	8 years 8 months 12 days
Number of Options, Granted	148,855	307,988
Weighted average exercise price, Granted	$ 5.02	$ 21.05
Number of Options, StemoniX options exchanged for Vyant Bio options		(136,276)
Weighted average exercise price, StemoniX options exchanged for Vyant Bio options		$ 9.20
Number of Options, Vyant Bio options issued to StemoniX option holders		174,652
Weighted average exercise price, Vyant Bio options issued to StemoniX option holders		$ 7.20
Number of Options, assumed in Merger		11,168
Weighted average exercise price, Options assumed in Merger		$ 229.75
Number of Options, Exercised	(1,034)	(7,419)
Weighted average exercise price, Exercised	$ 4.80	$ 6.05
Number of Options, Forfeited	(141,306)	(34,462)
Weighted average exercise price, Forfeited	$ 17.64	$ 18.45
Number of Options, Expired	(42,235)	(2,777)
Weighted average exercise price, Expired	$ 36.33	$ 9.60
Number of Options, Ending Balance	428,301	464,021	151,147
Weighted average exercise price, Ending Balance	$ 14.97	$ 20.95	$ 9.10
Number of Options, Exercisable	232,175	127,119
Weighted average exercise price, Exercisable	$ 18.18	$ 27.90
Weighted average remaining contractual term, Exercisable	6 years 4 months 24 days	7 years 1 month 6 days

Schedule of Share Based Compens

Schedule of Share Based Compensation Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 1,186	$ 1,003
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	782	973
Shares Issued For Services [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 404	$ 30

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Mar. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option exercisable term		6 years 4 months 24 days	7 years 1 month 6 days
Additional shares available for grant		428,301	464,021	151,147
Number of options, granted		148,855	307,988
Additional shares available for grant		533,495
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value		$ 10.23	$ 17.55
Unrecognized compensation cost		$ 1.6
Weighted average period		2 years 2 months 12 days
Frozen Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option exercisable term		10 years
2015 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares available for grant		38,376
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting rate	25%
2021 Equity Incentive Plan [Member] | Officers Key Employees and NonEmployee Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares available for grant		900,000
2021 Equity Incentive Plan [Member] | Officers and Other Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	230,300
2021 Equity Incentive Plan [Member] | Independent Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	15,618
2021 Equity Incentive Plan [Member] | Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	1,735

Schedule of Customers Represent

Schedule of Customers Representing Revenues (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	42%	18%
Customer B [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10%	9%
Customer C [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	4%	11%
Customer D [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	15%	1%
Customer E [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10%	6%
Customer F [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage		19%

Segment Information and Risk _3

Segment Information and Risk Concentration (Details Narrative) - Revenue Benchmark [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer Concentration Risk [Member] | Three Customers [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	77%	47%
Geographic Concentration Risk [Member] | Outside of United States [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	47%	21%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended	3 Months Ended			12 Months Ended
	Mar. 12, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Feb. 23, 2021	Feb. 21, 2021	Aug. 21, 2020
Related Party Transaction [Line Items]
Proceeds from sale of convertible note						$ 5,022
Repayments of Related Party Debt		$ 39	$ 89
[custom:PaymentForThirdPartyCollaborationArrangement]			$ 60
Merger Agreement [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock								28,778
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock					28,778		28,778
Warrants exercise price					$ 29.5295		$ 29.5295		$ 29.5295
2020 Convertible Notes [Member]
Related Party Transaction [Line Items]
Proceeds from sale of convertible note	$ 5,000			$ 3,900	$ 1,500

Contingencies and Commitments (

Contingencies and Commitments (Details Narrative) $ in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 AUD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and Development Expense	$ 6,772		$ 4,273
Australian Adult Clinical Trial [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and Development Expense		$ 3.9

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)						12 Months Ended
	Mar. 29, 2023	Mar. 24, 2023	Mar. 13, 2023	Mar. 07, 2023	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 09, 2023	Jan. 31, 2022
Subsequent Event [Line Items]
Operating lease obligation						$ 1,614,000	$ 690,000		$ 1,200,000
Operating Lease, Payments						$ 265,000	$ 509,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Insurance policies	$ 1,700,000
Subsequent Event [Member] | Vivo Pharm [Member]
Subsequent Event [Line Items]
Equipment Expense				$ 200,000
Operating Lease, Payments			$ 200,000
Subsequent Event [Member] | San Diego Office And Laboratory Lease Agreement [Member]
Subsequent Event [Line Items]
Termination fee								$ 45,000
Operating lease obligation								$ 1,200,000
Subsequent Event [Member] | Equity Distribution Agreement [Member] | Canaccord Genuity LLC [Member]
Subsequent Event [Line Items]
Aggregate offering price		$ 20,000,000
Subsequent Event [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]
Subsequent Event [Line Items]
Aggregate offering price		$ 15,000,000
Cash Preservation Plan [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Termination benefits					$ 954,000